Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
  • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
  • C07D239/72—Quinazolines; Hydrogenated quinazolines
  • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
  • C07D239/80—Oxygen atoms
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
  • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
  • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
  • A61K31/52—Purines, e.g. adenine
  • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
  • A61P11/06—Antiasthmatics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P13/00—Drugs for disorders of the urinary system
  • A61P13/12—Drugs for disorders of the urinary system of the kidneys
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/06—Antipsoriatics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P19/00—Drugs for skeletal disorders
  • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P19/00—Drugs for skeletal disorders
  • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
  • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
  • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/08—Antiepileptics; Anticonvulsants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P27/00—Drugs for disorders of the senses
  • A61P27/02—Ophthalmic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
  • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
  • A61P31/14—Antivirals for RNA viruses
  • A61P31/18—Antivirals for RNA viruses for HIV
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
  • A61P35/02—Antineoplastic agents specific for leukemia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/02—Immunomodulators
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/02—Immunomodulators
  • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/08—Antiallergic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
  • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
  • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

• the invention relates to spirotricyclic derivatives, the process for their preparation, and their use as phosphodiesterase inhibitors.
• Phosphodiesterases play an important role in various biological processes by hydrolysing the key second messengers adenosine and guanosine 3',5'-cyclic monophosphates (cAMP and cGMP respectively) into their corresponding 5'- monophosphate nucleotides. Therefore, inhibition of PDE activity produces an increase of cAMP and cGMP intracellular levels that activate specific protein phosphorylation pathways involved in a variety of functional responses.
• PDE7 is a cAMP-specific PDE.
• PDE7 activity or protein has been detected in T-cell lines, B-cell lines, airway epithelial (AE) cell lines and several foetal tissues.
• AE airway epithelial
• Increasing cAMP levels by selective PDE7 inhibition appears to be a potentially promising approach to specifically block or modulate T-cell and B-cell mediated immune responses.
• Further studies have demonstrated that elevation of intracellular cAMP levels can modulate inflammatory and immunological processes. This selective approach could presumably be devoid of the side effects associated with known selective PDE inhibitors (e.g. PDE3 or PDE4 selective inhibitors) and which limit their use.
• a functional role of PDE7 in T-cell activation has also been disclosed; therefore selective PDE7 inhibitors are candidates for the treatment of T-cell-related diseases.
• AE cells actively participate in inflammatory airway diseases by liberating mediators such as arachidonate metabolites and cytokines.
• Selective inhibition of PDE7 may be a useful anti-inflammatory approach for treating AE cells related diseases.
• B cells are well known key players in the allergic response, then selective PDE7 inhibitors are candidates for the treatment of B-cell-related diseases.
• WO 88/01508 discloses compounds of formula
• R is H, alkyl, alkoxyalkyl, hydroxyalkyl, halo, cyano, carbamoyl, alkyl carbamoyl, formyl, alkylamino or amino;
• X is -(CR4R5)a-NR6-(CR4R5)b-;
• Rl , R2, R3, and R5 are H or alkyl;
• R5 groups on vicinal carbon atoms may together form a carbon-carbon double bond; and geminal R4 and R5 groups may together form a spiro substitutent, -(CH2)d-, where -d is 2 to 5; or a pharmaceutically acceptable salt thereof. These compounds are described as cardiotonics.
• WO 00/66560 discloses compounds of formula
• the present invention provides compounds, which are PDE inhibitors, preferably PDE7 inhibitors, of formula (I)
• n 1, 2 or 3
• R 1 is selected from CH 3 , Cl, Br and F and,
• R 2 is selected from,
• ⁇ Q 1 is a single bond or a linear or branched (CrC ⁇ alkylene group
• ⁇ Q 2 is a saturated 4 to 6-membered heterocycle comprising one or two heteroatoms selected from O or N;
• ⁇ Q 3 is a linear or branched (C 1 -C 6 )alkylene group
• ⁇ the atom of Q 2 bound to Q 1 is a carbon atom
• ⁇ the atom of Q bound to Q 3 is a carbon atom
• R is selected from H and (CrC 6 )alkyl
• R 9 is selected from H, CN, OH, OCH 3 , SO 2 CH 3 , SO 2 NH 2 and (d-C ⁇ alkyl, and,
• R 4 and R 5 are the same or different and are selected from H and R 3 ; or their racemic forms, their isomers and their pharmaceutically acceptable derivatives.
• These compounds are selective PDE7 inhibitors. They can be used in the treatment of various diseases, such as T and B-cell-related diseases, autoimmune diseases, osteoarthritis, rheumatoid arthritis, multiple sclerosis, osteoporosis, chronic obstructive pulmonary disease (COPD), asthma, allergic rhinitis, allergy, cancer such as leukemia, acquired immune deficiency syndrome (ALDS), allergy, inflammatory bowel disease (IBD), ulcerative colitis, Crohn's disease, pancreatitis, dermatoses such as psoriasis and atopic dermatitis, glomerulonephritis, conjunctivitis, autoimmune diabete, graft rejection, epilepsy, muscular atrophy or systemic lupus erythematosus.
• diseases such as T and B-cell-related diseases, autoimmune diseases, osteoarthritis, rheumatoid arthritis, multiple sclerosis, osteoporosis, chronic obstructive pulmonary
• the invention further relates to a compound of formula (I) as a medicament.
• the invention further concerns the use of a compound of formula (I) for the manufacture of a medicament for the prevention or the treatment of disorders for which therapy by a PDE7 inhibitor is relevant.
• the invention also provides a method for the treatment of a disorder for which therapy by a PDE7 inhibitor is relevant, comprising administering to a mammal in need thereof an effective amount of compound of formula (I).
• the invention also concerns a pharmaceutical composition
• a pharmaceutical composition comprising a compound of formula (I) together with a pharmaceutically acceptable carrier, excipient, diluent or :' delivery system.
• the invention also relates to a process for the preparation of compounds of formula (I).
• the present invention provides compounds, which are PDE7 inhibitors, having formula (I) wherein R , R and m are as defined above.
• R is H or (Ci-C ⁇ jalkyl
• R and R are the same or different and are selected from H and (C ⁇ -C 6 )alkyl
• R 5 is selected from R 4 , H and ( -C ⁇ alkyl.
• Another preferred group of compounds of formula (I) is the one in which R 2 is (C ⁇ - C 6 )alkyl,
• said alkyl group being 1) substituted with 1 to 3 groups, preferably 1, selected from
• R 4 and R 5 are the same or different and are selected from H and R 3 .
• ⁇ Q 1 is a single bond or a linear or branched (C 1 -C 6 )alkylene group
• ⁇ Q 2 is a saturated 4 to 6-membered heterocycle comprising a nitrogen atom
• ⁇ Q 3 is a linear (C 1 -C 4 )alkylene group
• ⁇ Q 4 is a 5 or 6-membered, aromatic heterocycle comprising 1 to 4 nitrogen atoms, said heterocycle being optionally substituted with a methyl;
• the atom of Q bound to Q is a carbon atom
• the atom of Q 4 bound to Q 3 is a carbon atom
• R 2 is Q 1 -Q 2 -Q 3 -Q 4 wherein, ⁇ Q 1 is a single bond; ⁇ Q 2 is a saturated 4 to 6-membered heterocycle comprising a nitrogen atom, preferably azetidine;
• ⁇ Q 4 is a 5-membered, aromatic heterocycle comprising 2 nitrogen atoms, said heterocycle being optionally substituted with a methyl;
• ⁇ the atom of Q bound to Q is a carbon atom
• ⁇ the atom of Q 4 bound to Q 3 is a carbon atom.
• R ⁇ is Cl or F. . m is 2.
• R 1 is Cl or F and m is 2.
• linear or branched (C ⁇ -C 6 )alkylene group represent a carbon atom chain, linear or branched containing from 1 to 6 carbon atoms. Exemples of such (C ⁇ -
• C 6 )alkylene are methylene, ethylene, isopropylene, tert-butylene and the like.
• the term "(C ⁇ -C 6 )alkyl” represent a linear or branched carbon atom chain containing from 1 to 6 carbon atoms.
• Example of "(C 1 -C 6 )alkyl” are methyl, ethyl, propyl, butyl, isopropyl, tert-butyl and the like.
• saturated 4 to 6-membered heterocycle comprising one or two heteroatoms selected from nitrogen or oxygen
• azetidine pyrrolidine, piperidine, tetraliydrofurane, tetrahydropyrane, morpholine and piperazine.
• a preferred "saturated 4 to 6-membered heterocycle comprising a nitrogen atom or an oxygen atom” is azetidine.
• said heterocycle is 5 or 6-membered, aromatic, and comprises 1 or 2 nitrogen atoms. Examples of such groups are pyridyl, pyrazolyl and imidazolyl.
• the compounds utilized in the invention include pharmaceutically acceptable derivatives of compounds of formula (I) such as solvates, hydrates, pharmaceutically acceptable salts and polymorphs (different crystalline lattice descriptors).
• Pharmaceutically acceptable salts of a compound of formula (I) include salts having a basic part and salts having an acidic part.
• the expression pharmaceutically acceptable salt of a compound of formula (I) having a basic part should be understood to refer to the addition salts of the compounds of formula (I) which may be formed from non-toxic inorganic or organic acids such as, for example, hydrobromic, hydrochloric, sulfuric, phosphoric, nitric, acetic, succinic, tartaric, citric, maleic, hydroxymaleic, benzoic, fumaric and toluenesulfonic acid salts, and the like.
• the various quaternary ammonium salts of the derivatives (I) are also included in this category of compounds of the invention.
• the expression pharmaceutically acceptable salt of a compound of formula (I) having an acidic part is understood to refer to the usual salts of the compounds of formula (I) which may be formed from non-toxic inorganic or organic bases such as, for example, the hydroxides of alkali metals and alkaline-earth metals (sodium, potassium, magnesium and calcium), amines (dibenzylethylenediamine, trimethylamine, piperidine, pyrrolidine, benzylamine and the like) or alternatively quaternary ammonium hydroxides such as tetramethylammonium hydroxide. (See also “Pharmaceutical salts” by Berge S.M. et al. (1997) J. Pharm. Sci. 66: 1-19, which is incorporated herein by reference.).
• the invention also relates to a process for preparing the above compounds of formula (I), said process comprising the following steps: (1) reacting a compound la of formula (I), said process comprising the following steps: (1) reacting a compound la of formula (I), said process comprising the following steps: (1) reacting a compound la of formula (I), said process comprising the following steps: (1) reacting a compound la of formula (I), said process comprising the following steps: (1) reacting a compound la of formula (I), said process comprising the following steps: (1) reacting a compound la of formula (I), said process comprising the following steps: (1) reacting a compound la of formula (I), said process comprising the following steps: (1) reacting a compound la of formula (I), said process comprising the following steps: (1) reacting a compound la of formula (I), said process comprising the following steps: (1) reacting a compound la of formula (I), said process comprising the following steps: (1) reacting a compound la of formula (I), said process comprising the following steps: (1) reacting a compound
• R 1 and m are as defined above, with a compound of formula R 2 -LG wherein R 2 is as defined in the summary of the invention and LG is a leaving group such as chloride, bromide, iodide, triflate, mesylate, tosylate or nosylate, in the presence of a base, to give a compound of formula (I)
• compositions which are appropriate for the nature, and severity of the complaint to be treated.
• the daily dose in humans is usually between 1 mg and 1 g of product, which may be taken in one or more individual doses.
• compositions are prepared in forms which are compatible with the intended route of administration, such as, for example, tablets, coated tablets, capsules, mouthwashes, aerosols, powders for inhalation, suppositories, enemas, foams (such as rectal foams) gels or suspensions.
• compositions are prepared by methods which are familiar to those skilled in the art and comprise from 0.5 to 60% by weight of active principle (compound of the invention) and 40 to 99.5% by weight of a pharmaceutical vehicle or carrier which is appropriate and compatible with the active principle and the physical form of the intended composition.
• Solid form preparations include powders, tablets, dispersible granules, capsules, cachets, and suppositories.
• a solid carrier can be one or more substances which may also act as diluents, flavouring agents, solubilizers, lubricants, suspending agents, binders, or tablet disintegrating agents; it can also be an encapsulating material.
• the carrier is a finely divided solid, which is in a mixture with the finely divided active component.
• the active component is mixed with the carrier having the necessary binding properties in suitable proportions and compacted in the shape and size desired.
• the powders, tablets, cachets or encapsulated forms for capsules preferably contain 5% to about 70% of the active component.
• Suitable carriers are magnesium carbonate, magnesium stearate, talc, lactose, sugar, pectin, dextrin, starch, tragacanth, methyl cellulose, sodium carboxymethyl cellulose, a low- melting wax, cocoa butter, and the like.
• Tablets, powders, cachets, and capsules can be used as solid dosage forms suitable for oral administration.
• the drug may be delivered as a spray (either in a pressurized container fitted with an appropriate valve or in a non-pressurized container fitted with a metering valve).
• Liquid form preparations include solutions, suspensions, and emulsions.
• Liquid preparations can also be formulated in solution in aqueous polyethylene glycol solution.
• Aqueous solutions for oral administration can be prepared by dissolving the active component in water and adding suitable colorants, flavouring agents, stabilizers, and thickening agents as desired.
• Aqueous suspensions for oral use can be made by dispersing the finely divided active component in water together with a viscous material such as natural synthetic gums, resins, methyl cellulose, sodium carboxymethyl cellulose, and other suspending agents known to the pharmaceutical formulation art.
• a viscous material such as natural synthetic gums, resins, methyl cellulose, sodium carboxymethyl cellulose, and other suspending agents known to the pharmaceutical formulation art.
• a low-melting wax such as a mixture of fatty acid glycerides and cocoa butter is first melted and the active ingredient is dispersed therein by, for example, stirring. The molten homogeneous mixture is then poured into convenient sized molds and allowed to cool and solidify.
• Enemas are obtained according to known procedures to prepare solutions adapted for rectal administration. Foams are prepared according to known methods (these foams can notably be similar to those used to administer a drug such as 5-ASA for treating rectocolite).
• the pharmaceutical preparation is in unit dosage form. In such form, the preparation is divided into unit doses containing appropriate quantities of drug.
• the unit dosage form can be a packaged preparation, the package containing discrete quantities of the preparation, for example, packaged tablets, capsules, and powders in vials or ampoules.
• the unit dosage form can also be a capsule, cachet, or tablet itself, or it can be the appropriate number of any of these packaged forms.
• the compounds of the invention are PDE inhibitors, and particularly PDE7 inhibitors.
• selective PDE7 inhibitors refers to a compound which have an IC 50 for PDE7 at least 5 times lower than the IC 50 for a PDE distinct from PDE7, and preferably at least 10 times, 15 times, 20 times, 30 times, 40 times,
• a PDE distinct from PDE7 refers preferably to a PDE chosen from PDE1, PDE3, PDE4 or PDE5.
• the compounds of the invention and more particularly the family of compounds given as examples in the present description, have an IC 50 value for the enzyme PDE7 which is often 100 times lower than the value of their IC 50 for a PDE distinct from PDE7, in particular
• Compounds of the invention can be used in the treatment of various diseases, as they can modulate inflammatory and immunological processes due to the increase of intracellular cAMP levels.
• diseases that can be treated include T and B-cell-related diseases, autoimmune diseases, osteoartliritis, rheumatoid arthritis, multiple sclerosis, osteoporosis, chronic obstructive pulmonary disease (COPD), asthma, cancer such as leukemia, acquired immune deficiency syndrome (AIDS), allergy, inflammatory bowel disease (LBD), ulcerative colitis, Crohn's disease, pancreatitis, dermatoses such as psoriasis and atopic dermatitis, glomerulonephritis, conjunctivitis, autoimmune diabete, graft rejection, epilepsy, muscular atrophy or systemic lupus erythematosus.
• Compounds of the invention are particularly useful for the treatment of asthma, allergy, atopic dermatitis, osteoporosis and cancer such as leukemia.
• Jh scheme 1, R , R and m are as defined in the summary of the invention and LG is a leaving group such as chloride, bromide, iodide, triflate, mesylate, tosylate or nosylate.
• Compound la can be prepared using processes disclosed in PCT/EP02/03594.
• the dimethylformamide was then removed by evaporation and the residue was partitioned between dichloromethane and a satured solution of Na 2 S 2 O 4 .
• the organic layer was dried over sodium sulfate, filtered, and concentrated under reduced pressure to give the intermediate b.
• R j Cl
• R 2 -CH 2 -CH 2 -NH-CH 2 -CO-NH 2
• m 2.
• the crude compound was purified by column chromatography (silica 5g eluting with 2% to 5% methanol (with P/o ammonia) in dichloromethane). The compound was washed with diethyl ether, filtered and dried under vaccum to give the title product (8mg, 9% two steps).
• the crude material was purified by a first column chromatography (silica gel 10 g, eluting with P/o methanol (with P/o ammonia) in dichloromethane) and followed by a second column chromatography (silica gel 10 g, eluting with P/o to 5% methanol in dichloromethane) to afford the title compound
• the capacity of the compounds of the invention to inhibit cyclic nucleotide phosphodiesterases was evaluated by measuring their IC 50 (concentration necessary to inhibit the enzymatic activity by 50 %).
• PDE1C, PDE3A, PDE4B2, PDE7A1, PDE7B and PDE11A were cloned and expresse in insect cells Sf21 using the baculovirus expression system and the cell culture supernatant was used directly as enzyme source. Measurement of the enzymatic activity for the various types of PDE was then made according to a method adapted from WJ. Thompson et al. 1979, Advances in Cyclic Nucleotide Research, Vol. 10 : 69-92, ed. G. Brooker et al. Raven Press, NY.
• the substrate used was tritiated cGMP (16 Ci/mmol) for PDE1 and PDE11 and tritiated cAMP (35 Ci/mmol) for PDE3, PDE4 and PDE7.
• the substrate concentration was 28nM for PDE1, PDE11 and 13nM for PDE3, PDE4 and PDE7 .
• the enzymatic reaction was stopped after 30 min by addition of SPA yttrium silicate beads (Amersham).
• IC 50 ( ⁇ M) were determined for examples 1 to 6 and were found to be below l ⁇ M.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Life Sciences & Earth Sciences (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• Animal Behavior & Ethology (AREA)
• Pharmacology & Pharmacy (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• Immunology (AREA)
• Physical Education & Sports Medicine (AREA)
• Pulmonology (AREA)
• Rheumatology (AREA)
• Orthopedic Medicine & Surgery (AREA)
• Pain & Pain Management (AREA)
• Neurology (AREA)
• Diabetes (AREA)
• Oncology (AREA)
• Neurosurgery (AREA)
• Virology (AREA)
• Biomedical Technology (AREA)
• Hematology (AREA)
• Molecular Biology (AREA)
• Ophthalmology & Optometry (AREA)
• Communicable Diseases (AREA)
• Tropical Medicine & Parasitology (AREA)
• Emergency Medicine (AREA)
• Endocrinology (AREA)
• Obesity (AREA)
• AIDS & HIV (AREA)
• Transplantation (AREA)
• Dermatology (AREA)
• Urology & Nephrology (AREA)
• Epidemiology (AREA)

Priority Applications (12)

Applications Claiming Priority (2)

Publications (1)

Family

ID=31896987

Family Applications (1)

Country Status (30)

Cited By (8)

Families Citing this family (24)

Citations (2)

Family Cites Families (8)

• 2002
  • 2002-09-17 EP EP20020292275 patent/EP1400244A1/en not_active Withdrawn
• 2003
  • 2003-09-08 AU AU2003259496A patent/AU2003259496A1/en not_active Abandoned
  • 2003-09-08 CA CA 2499330 patent/CA2499330C/en not_active Expired - Fee Related
  • 2003-09-08 MX MXPA05002913A patent/MXPA05002913A/es active IP Right Grant
  • 2003-09-08 HR HR20050223A patent/HRP20050223A2/hr not_active Application Discontinuation
  • 2003-09-08 OA OA1200500073A patent/OA12924A/en unknown
  • 2003-09-08 EP EP20030797455 patent/EP1542694A1/en not_active Withdrawn
  • 2003-09-08 JP JP2004537412A patent/JP2006501277A/ja not_active Withdrawn
  • 2003-09-08 WO PCT/IB2003/003965 patent/WO2004026818A1/en not_active Ceased
  • 2003-09-08 PL PL37597703A patent/PL375977A1/xx not_active Application Discontinuation
  • 2003-09-08 KR KR1020057004511A patent/KR20050057371A/ko not_active Ceased
  • 2003-09-08 AP AP2005003251A patent/AP2005003251A0/xx unknown
  • 2003-09-08 EA EA200500312A patent/EA200500312A1/ru unknown
  • 2003-09-08 CN CNA038221284A patent/CN1681507A/zh active Pending
  • 2003-09-08 BR BR0314379A patent/BR0314379A/pt not_active IP Right Cessation
  • 2003-09-16 AR ARP030103355 patent/AR041271A1/es unknown
  • 2003-09-16 TW TW92125477A patent/TWI251590B/zh not_active IP Right Cessation
  • 2003-09-16 PA PA8582801A patent/PA8582801A1/es unknown
  • 2003-09-16 PE PE2003000943A patent/PE20050073A1/es not_active Application Discontinuation
  • 2003-09-17 UY UY27986A patent/UY27986A1/es not_active Application Discontinuation
  • 2003-09-17 GT GT200300201A patent/GT200300201A/es unknown
  • 2003-09-17 HN HN2003000285A patent/HN2003000285A/es unknown
  • 2003-09-17 US US10/667,111 patent/US7429598B2/en not_active Expired - Fee Related
• 2005
  • 2005-02-16 ZA ZA200501381A patent/ZA200501381B/xx unknown
  • 2005-02-17 IS IS7700A patent/IS7700A/is unknown
  • 2005-03-10 CR CR7728A patent/CR7728A/es not_active Application Discontinuation
  • 2005-03-11 EC ECSP055671 patent/ECSP055671A/es unknown
  • 2005-03-16 CO CO05024530A patent/CO5540391A2/es not_active Application Discontinuation
  • 2005-03-17 MA MA28153A patent/MA27439A1/fr unknown
  • 2005-03-17 TN TNP2005000073A patent/TNSN05073A1/fr unknown
  • 2005-04-05 NO NO20051695A patent/NO20051695L/no not_active Application Discontinuation

Patent Citations (3)

Non-Patent Citations (2)

Also Published As

Similar Documents

Legal Events